There is a pretty good reason that the Pfizer RCT doesn't show excess mortality benefit. It wasn't designed to study that. The recruited population is mostly healthy as individuals with multiple risk factors were excluded. For example the proportion of the study group over 65 and the proportion with at least 1 comorbidity is much smaller than the population as a whole. The studied group was very unlikely to experience mortality in the first place so a much larger study would be needed to show any evidence of an effect on mortality. The difference between 17 and 21 is not statistically significant.

In the absence of a large enough RCT we're left with observational studies and there are a ton of these now. The observational data shows a large mortality benefit in the vaccinated population and I'm not aware of a single observational study that shows the opposite, but I suppose there could be one out there that I have missed.

The preponderance of the evidence is pretty strongly in favor of the vaccinated population experiencing lower mortality than the unvaccinated population.